Clinical trials: Metastatic Gastrointestinal Cancer
Metastatic Colorectal Cancer
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
This is an open-label, parallel designed study to assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of a recombinant anti-EGFR monoclonal antibody (CPGJ602) in patients with at least one prior…
- Trial name
- NCT03356158
- Testing
- CPGJ602, Cetuximab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Metastatic Colorectal Cancer
Metastatic Colorectal Cancer Database
The metastatic ColoRectal Cancer (mCRC) Database base contains data collected during the regular clinical patient management in Centre Georges Francois Leclerc, Dijon.
- Trial name
- NCT04031625
- Testing
- Metastatic Colorectal Cancer Database
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Georges Francois Leclerc
Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Randomized phase II trial to compare the effectiveness of bortezomib with or without gemcitabine in treating patients who have metastatic pancreatic cancer.
- Trial name
- NCT00052689
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer…
- Trial name
- NCT00026338
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 173 sites in United States, Argentina and 17 more
- Volunteers
- 569 people
- Sponsor
- NCIC Clinical Trials Group
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
- Trial name
- NCT07539155
- Testing
- Intratumoral MMR Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Gastrointestinal Stromal Tumor, Sarcoma
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally…
- Trial name
- NCT00041249
- Testing
- brostallicin
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumor, Metastatic Colorectal Cancer
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
The primary purpose of this study is to find the highest tolerated dose of the study drugs: capecitabine, oxaliplatin, bevacizumab, and dasatinib given in combination to subjects with advanced solid tumors.
- Trial name
- XAD (NCT00920868)
- Testing
- dasatinib, bevacizumab, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Herbert Hurwitz, MD
Extranodal Extension
Tumor Deposits in Colorectal Cancers
Tumor deposits (TDs) are emerging as an adverse prognostic factor in colorectal cancers (CRCs), but they are quite ignored in the current staging system.
- Trial name
- TD (NCT05923450)
- Testing
- Colorectal Resection
- Volunteers
- 243 people
- Sponsor
- University of Campania Luigi Vanvitelli
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
The purpose of this study is to determine the efficacy of an oral investigational drug in patients with refractory metastatic colorectal cancer after receiving prior therapy with 5-fluorouracil in combination with irinotecan…
- Trial name
- NCT00044343
- Testing
- lapatinib
- Where
- 57 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Colo-rectal Cancer
A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations
This is an open-label, unicentre, single-arm Phase 2 study of encorafenib and cetuximab as rechallenge treatment in patients with BRAF V600E-mutant metastatic colorectal cancer after previous therapy with BRAF inhibitors-based…
- Trial name
- REFISH (NCT07178717)
- Testing
- Rechalange with bevacizumab + encorafenib
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Metastatic Colorectal Cancer
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an…
- Trial name
- AFEMA (NCT03279289)
- Testing
- Aflibercept, Irinotecan, folinic acid (dl racemic)
- Where
- Spain
- Volunteers
- 170 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Pancreatic Cancer
QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer
Primary End Point: To compare the overall survival (OS) using QYHJ Granules or Xeloda as the second therapy in patients with metastatic pancreatic cancer.
- Trial name
- NCT01796782
- Testing
- Xeloda, QYHJ Granules
- Volunteers
- 60 people
- Sponsor
- Fudan University
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Gastric Carcinoma
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT00970138
- Testing
- apatinib tablet
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Colorectal Cancer, Advanced Cancer
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models.
- Conditions
- Colorectal Cancer, Advanced Cancer, Metastatic Cancer
- Trial name
- TRAHD (NCT03714958)
- Testing
- HDM201, Trametinib
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Leon Berard
Metastatic Colorectal Cancer
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.
- Trial name
- NCT03645876
- Testing
- SHR-1210, BP102, oxaliplatin
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Colorectal Cancer, RAS Mutation
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
A phase II clinical study of Sintilimab (IBI308) combined with Bevacizumab, Oxaliplatin and Capecitabine regimen as first-line treatment in patients with RAS-mutant and microsatellite stable metastatic colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable
- Trial name
- NCT04194359
- Testing
- Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00423696
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- 15 sites in France
- Volunteers
- 145 people
- Sponsor
- UNICANCER